# NeuVasQ Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuvasq-biotechnologies

- Industry: Biotechnology
- Headquarters: Charleroi, Belgium
- Website: www.neuvasq.com
- Total disclosed funding: $18M
- Latest round: Series A (Jul 29, 2021)
- Investors on record: 5

## About

Based in Charleroi, Belgium, and founded in 2021 as a spin-off of the Université Libre de Bruxelles (ULB) and Prof. Benoit Vanhollebeke, NeuVasQ Biotechnologies operates as a biotechnology company that develops novel therapies to restore blood-brain barrier function in acute neurological disorders. In June 2021, NeuVasQ Biotechnologies Ltd raised EUR 20 million in Series A funding led by investor Newton Biocapital Partners, with participation from Investsud, SFPI-FPIM, SRIW, and Theodorus.

The firm works in developing pharmaceuticals and novel therapies to restore blood-brain barrier (BBB) functions to help restore the lost functionality to the neurovasculature system usually seen in acute neurological disorders such as stroke, epilepsy, and neurodegenerative diseases like Alzheimer’s.

## Funding rounds

- Series A, Jul 29, 2021, $18M — SFPI-FPIM, Seido Capital, SRIW, Newton Biocapital Partners, Investsud

## Investors

- SFPI-FPIM — Series A
- Seido Capital (https://capitalatlas.ai/funds/seido-capital) — Series A
- SRIW — Series A
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series A
- Investsud — Series A